Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Prevalence and correlates of obstructive lung disease among people who inject drugs, San Diego, California

Hayley J. Koslik, Jisha Joshua, Jazmine Cuevas-Mota, Daniel Goba, Eyal Oren, John E. Alcaraz, Richard S. Garfein

San Diego State University, School of Public Health, 5500 Campanile Drive, San Diego, CA, 92182, United States
University of California San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, United States

ARTICLE INFO

Keywords:
- Obstructive lung disease
- Smoking
- Mycobacterium tuberculosis infection
- Injection drug use

ABSTRACT

Background: Pulmonary tissue damage leading to obstructive lung disease (OLD) could result from intravenous administration of insoluble particles found in illicit drugs. This study described the prevalence and identified correlates of OLD among people who inject drugs (PWID).

Methods: In 2012–2016, a community-based cohort of PWID who had injected within the past month were enrolled in a study to assess HIV, hepatitis C virus (HCV) and Mycobacterium tuberculosis (Mtbc) infections and their related risk factors. Data were obtained through face-to-face interviews, serological testing and spirometry. Baseline data were used for a cross-sectional analysis of the prevalence and correlates of OLD, defined as FEV1/FVC < 0.7. Univariate and multivariable logistic regression were used to identify factors associated with OLD.

Results: Among 516 participants who had complete spirometry and interview results, the mean age was 43.3 years, 73.6% were male, 9.5% were Black, 91.1% smoked cigarettes and 18.2% had OLD. Few (9.6%) PWID with OLD reported a previous diagnosis of COPD although many (44.7%) reported related symptoms. Black race (AOR = 2.66, 95%CI: 1.37, 5.17), pack-years smoked (AOR = 1.06/5 years, 95%CI: 1.01, 1.12), and duration of injection drug use (AOR = 1.13, 95%CI: 1.01, 1.27) were independently associated with OLD after controlling for age.

Conclusions: The prevalence of OLD was high in this cohort and associated with Black race and cigarette smoking—known risk factors. In addition, OLD prevalence increased with greater duration of injection drug use, suggesting a link between cumulative exposure to injected insoluble particles and OLD. Further examination of these adulterants and lung pathology are needed.

1. Introduction

Obstructive lung disease (OLD) is a group of conditions characterized by episodic or persistent airflow limitation that makes breathing difficult, which may be partially irreversible (Global Initiative for Chronic Obstructive Lung Disease, 2018). These conditions include chronic obstructive pulmonary disease (COPD) and asthma, and are characterized by symptoms of shortness of breath, chest tightness, wheezing, cough, and mucus production. Among United States (U.S.) adults, the number of physician-diagnosed COPD and asthma cases annually is a staggering 14.8 and 25 million, respectively (Office of Disease Prevention and Health Promotion, 2019), and globally the number has reached 251 and 235 million cases, respectively (World Health Organization (WHO), 2017, 2019). COPD is the fourth leading cause of death in the U.S. (Heron, 2018) and remains the third leading cause of death worldwide (World Health Organization (WHO), 2018). Mortality outcomes for individuals with COPD vary by patient phenotype (whether there is overlap with asthma, moderate/severe exacerbations with chronic bronchitis or emphysema, etc.), but is predominantly due to disease progression (Golpe et al., 2018). OLD costs the U.S. healthcare system an estimated $50 billion annually in COPD-related expenditures – $30 billion going to direct healthcare costs, and the rest to indirect costs, such as patients’ inability to work or time taken off from work (Guarascio et al., 2013) – and $20.7 billion per year in asthma-related expenditures (Office of Disease Prevention and Health Promotion, 2019).

The leading risk factor for COPD is cigarette smoking (Bhatt et al., 2018), but studies have also reported associations with older age (de Marco et al., 2011), low socioeconomic status (Wheaton et al., 2015), human immunodeficiency virus (HIV) infection (Drummond et al., 2018).
2.1. Study design

The present study used baseline data from the Study of Tuberculosis, AIDS, and Hepatitis C Risk (STAHR II) cohort for a cross-sectional analysis of the prevalence and correlates of OLD among PWID. STAHR II was a prospective cohort study in which community-recruited PWID who had injected at least once in the prior month (actively injecting) were enrolled in 2012–2014, and followed for two years through semi-annual follow-up visits to determine the prevalence, incidence, and risk factors for Mycobacterium tuberculosis (Mtb), HIV, and hepatitis C virus (HCV) infections among PWID in San Diego, CA. STAHR II methods were published in detail elsewhere (Robertson et al., 2014).

2.2. Human subjects approval

The STAHR II study protocol was approved by an institutional review board at the University of California San Diego, and all participants provided written informed consent. The current analysis also received a Non-Human Subjects Research Determination from San Diego State University’s Human Research Protections Program.

2.3. Study population

Study participants were recruited through targeted sampling, which consisted of street outreach and posting flyers in areas where PWID generally gather (e.g., syringe exchange program sites), print and online advertising (e.g., local newspaper, Craigslist), as well as through participant referrals (Robertson et al., 2014). Eligible participants were at least 18 years old, spoke English or Spanish, had illicitly injected drugs in the past 30 days, were non-institutionalized (i.e., hospitalized, incarcerated or in-patient substance use treatment), and resided in San Diego County without plans to move away in the next 24 months.

2.4. Outcome measure

OLD status (yes/no) was determined at baseline by spirometry using a forced expiratory volume per second/forced vital capacity (FEV1/FVC) ratio without the use of bronchodilators. Spirometry was repeated three times in the same visit and then averaged according to 1994 American Thoracic Society recommendations (Standardization of Spirometry, 1994). OLD was defined as a fixed ratio FEV1/FVC value < 0.70 based on Global initiative for chronic Obstructive Lung Disease (GOLD) cut-offs (Güder et al., 2012).

2.5. Interview measures

Computer-assisted personal interviews were conducted at baseline by trained interviewers in a private setting and lasted an average of 60–90 min. Interviews collected information about potential correlates and known risk factors for OLD including socio-demographics (i.e., age, gender, race/ethnicity, homelessness), smoking status, lifetime and recent drug use and injection behaviors, symptoms and previous diagnosis of respiratory illness, and healthcare utilization.

Due to the non-linear relationship between age and risk of OLD, age (collected in years) was categorized for this analysis as a binary variable (< 40 years and ≥ 40 years) for consistency with other studies as this is the age that COPD symptoms typically begin (National Heart Lung and Blood Institute; COPD, 2020) and COPD prevalence increases (Ntirisos et al., 2018). Eight individuals reported being transsexual/transgender and were grouped by their preferred binary gender (male/female). Since prior studies found only Black race to be associated with OLD compared to other races (Chatila et al., 2006; Drummond et al., 2012), race was dichotomized for this analysis (Black/non-Black). For descriptive purposes, a non-binary race variable (Asian, Black, Hispanic, Other, White) was reported. Self-perceived homelessness was queried, “In the past 6 months, have you ever thought of yourself as homeless?” (yes or no).

To obtain cigarette smoking status, participants were asked about lifetime history of smoking (“Have you ever smoked at least 100 cigarettes in your entire life?” [yes/no]), and current smoking status (“Do you smoke cigarettes now?” [yes/no]). Responses to these questions were used to create a “cigarette smoking status” variable (never smoker, former smoker, current smoker). Pack-years of smoking among former and current smokers was calculated as the number of cigarettes smoked per day times the number of years smoked divided by 20. Participants were also asked if they had ever used marijuana or hash (yes/no).

To examine injection drug use practices, participants were asked to specify the number of years they had been injecting drugs (continuous) and the specific types of drugs (e.g., heroin, cocaine, methamphetamine) they had injected, smoked, or inhaled in their lifetime (yes/no). Types of heroin injected (black tar, white powder, brown powder, other) were assessed among those who reported injecting heroin in the past 6 months.

The main reasons for not seeking medical care in the past 6 months, if applicable, were grouped into 6 categories due to small sample sizes (visit not expected to be helpful, avoidance of bad news; fear of hostility, disrespect, or arrest; too embarrassed, ashamed, tired, sleepy, lazy, depressed, ill, weak, sick, or busy to go; transportation issues; no insurance, too expensive; or other). Questions also queried whether participants had received professional help for drug or alcohol use in...
their lifetime (yes/no), and if yes, the type of professional help received (drugs only, alcohol only, both), and the number of times help was received (continuous). Respiratory-related symptoms and previous diagnoses were also assessed.

2.6. Serologic testing

Following the interview, participants received pre-test counselling and serologic testing for HIV (Uni-Gold Recombigen, Trinity Biotech PLC, Bray, Ireland), HCV (OraQuick®, OraSure Technologies, Bethlehem, USA) and Mtb (QuantiferON-TB Gold In-Tube, Qiagen, Hilden, Germany) infection using commercially-available assays (described elsewhere) (Horyniak et al., 2017). Post-test counselling and referrals for care were also provided depending on test results.

2.7. Data analysis

Descriptive statistics were calculated for all variables. For skewed data we report medians and interquartile ranges (IQRs) instead of means. Bivariate associations were assessed between OLD and other covariates using chi-square tests for categorical variables and t-tests or Wilcoxon Rank Sum tests for continuous variables, and simple logistic regression. Covariates with a p-value < 0.10 in bivariate analysis or supported by the literature as potential risk factors for OLD were included in multivariable analyses. Collinearity was assessed using tolerance (< 0.1) and variance inflation (> 10) statistics.

A backwards stepwise regression procedure was used to determine factors independently associated with OLD. Pack-years smoked, age, and race were kept in models examining correlates of OLD to control for known risk factors (Chatila et al., 2006; Global Initiative for Chronic Obstructive Lung Disease, 2018). All other variables were only retained in the final model if they were significant at the alpha = 0.05 level. Statistical analyses were conducted using SAS version 9.4.

3. Results

Of the 573 STAHR II participants, 516 (90.5 %) had complete baseline spirometry and interview data for this analysis. Fifty-five participants had missing spirometry results because of either recent surgery or participant refusal precluded measurement. Most participants were 40 years of age or older (63.6 %), male (73.6 %), and non-Black (90.5 %). Overall, the mean number of years injecting drugs was 24.9 (± 13.8) and the median number of times injecting in the past 6 months was 200 (IQR 78–420). The most common drugs ever injected were heroin (85.6 %), methamphetamine (81.4 %), and cocaine (64.7 %) (lesser used drugs not shown and are described elsewhere) (Horyniak et al., 2017). Post-test counselling and referrals for care were also provided depending on test results.

### Table 1

| Overall (n = 516) | OLD (n = 94) | No OLD (n = 422) | p-value* |
|-------------------|-------------|-----------------|---------|
| Age, n (%)       |             |                 |         |
| < 40 years       | 188 (36.6)  | 25 (26.6)       | 163 (38.6) |
| ≥ 40 years       | 328 (63.4)  | 69 (73.4)       | 259 (61.4) 0.030 |
| Gender, n (%)    |             |                 |         |
| Male             | 380 (73.6)  | 72 (76.6)       | 308 (73.0) |
| Female           | 136 (26.3)  | 22 (23.4)       | 114 (27.0) 0.473 |
| Race (non-binary), n (%) |    |                 |         |
| Asian            | 4 (0.78)    | 0 (0.0)         | 4 (0.78) 0.987 |
| Black            | 49 (9.5)    | 17 (18.1)       | 32 (7.6) 0.004 |
| Hispanic         | 156 (30.2)  | 24 (25.5)       | 132 (31.3) 0.744 |
| Other            | 48 (9.3)    | 10 (10.6)       | 38 (9.0) 0.477 |
| White            | 259 (50.2)  | 43 (45.7)       | 216 (51.2) |
| Race (binary), n (%) |    |                 |         |
| Non-Black        | 467 (90.5)  | 77 (81.9)       | 390 (92.4) |
| Black            | 49 (9.5)    | 17 (18.1)       | 32 (7.6) 0.002 |
| Homeless in past 6 months, n (%) |    |                 |         |
| Yes              | 197 (38.2)  | 33 (35.1)       | 164 (38.9) |
| No               | 319 (61.8)  | 61 (64.9)       | 258 (61.1) 0.498 |
| History of smoking, n (%) |    |                 |         |
| Yes              | 45 (8.7)    | 8 (8.5)         | 37 (8.8) |
| No               | 470 (91.1)  | 85 (90.4)       | 385 (91.2) 0.959 |
| Missing**        | 1 (0.2)     | 1 (1.1)         | 0 (0.0) |
| Cigarette smoking status, n (%) |    |                 |         |
| Never smoked     | 45 (8.7)    | 8 (8.5)         | 37 (8.8) |
| Former smoker    | 30 (5.8)    | 5 (5.3)         | 25 (5.9) 0.901 |
| Current smoker   | 440 (85.3)  | 80 (85.1)       | 360 (85.3) 0.947 |
| Missing**        | 1 (0.2)     | 1 (1.1)         | 0 (0.0) |
| Pack-years of cigarette smoking, n (%) |    |                 |         |
| 1 (5.2–29)       | 15.5 (9.3–37) | 12.5 (4.5–25) | 0.002 |
| Form of heroin injected in past 6 months, n (%) |    |                 |         |
| Yes              | 442 (85.7)  | 84 (89.4)       | 358 (84.8) 0.355* |
| No               | 74 (14.3)   | 10 (10.6)       | 64 (15.2) |

### Table 2

Continued on next page
between groups, with PWID with OLD more often reporting that the “visit [was] not expected to be helpful, avoidance of bad news” (p = 0.021) and “fear of hostility, disrespect or arrest” (p = 0.065). No other respiratory symptoms or illnesses or healthcare utilization variables were associated with OLD.

In multivariable logistic regression analysis adjusting for age, pack years smoked, and Black race (Table 3), we observed a 13 % increase in the odds of OLD for every 5 pack-years injecting drugs (adjusted odds ratio [AOR] = 1.13, 95 % confidence interval [CI]: 1.01, 1.27). In the final model, OLD was also independently associated with Black race (AOR = 2.66, 95 % CI: 1.37, 5.17) and smoking history, with a 6 % increase in the odds of OLD for every 5 pack-years smoked (AOR = 1.06, 95 % CI:1.01, 1.12).

4. Discussion

This study found the prevalence of OLD to be 18.2 % among PWID in San Diego, CA. Black race, pack-years smoked, and duration of injection drug use were independently associated with OLD after adjusting for age. Although PWID with OLD have increased need for healthcare, access to and utilization of health services were not associated with OLD in this study.

The observed prevalence of OLD in this study is similar to that found among current and former PWID in Baltimore, MD (16.3 %) (Dummond et al., 2011). The prevalence among PWID is much higher than the general population where the prevalence of COPD is approximately 3.4 % (World Health Organization (WHO), 2017). This finding highlights the disparity faced by PWID potentially due to behavioral, economic, and environmental factors. Factors that might account for this disparity include a high prevalence of current smokers (Clarke et al., 2001), high rates of HIV (Alcabes and Friedland, 1995; Morris et al., 2011) and Mtb infection (Armenta et al., 2017; Byrne et al., 2015), socioeconomic disadvantage (Wheaton et al., 2015), and delayed detection and/or treatment of OLD due to healthcare stigma or limited access (Dummond et al., 2011; Neale et al., 2008). Our findings provide further evidence that OLD disproportionately affects PWID, and a multilevel approach is needed to address the disparity.

Our findings provide novel information about OLD among PWID. Nearly the entire cohort smoked cigarettes, and consistent with the evidence in a smoking population (Jaen Diaz et al., 2003), pack-years smoking was independently associated with OLD status. The fact that smoking was nearly ubiquitous in this cohort was a relative strength of the study in that it allowed for assessment of other correlates of OLD. Black race was found to be independently associated with OLD. Black race has been previously identified as a risk factor for early-onset COPD, defined as age < 55 years (Foreman et al., 2011). The older age category in this study included those considered for early-onset COPD in the prior study, which may explain the high prevalence of OLD among Blacks in this cohort. Higher prevalence of OLD among Blacks may occur because of greater vulnerability to the effects of tobacco smoking (Dummond et al., 2006). Despite smoking fewer cigarettes per day, Blacks with emphysema showed similar lung impairment to their White counterparts in the National Emphysema Treatment Trial (Chatila et al., 2006). Duration of injection drug use was also independently associated with OLD status. This comport with the hypothesis that exposure to non-soluble particles in illicit drugs or medications meant for oral use might increase the risk for OLD, because injection duration is a proxy for cumulative exposure to excipients.

The specific drug type or administration route (injected, smoked, or inhaled) was not associated with OLD. Without knowing the type or quantity of contaminants and lifetime frequency of exposure, it is difficult to assess whether specific drugs increase the risk of OLD. Assuming all drugs contain some contaminants, it is also the case that lack of specificity between drugs may mask any association. This hypothesis merits further investigation in a larger sample that more precisely measures the quantities and types of contaminants injected over time.

OLD is often not recognized among PWID in healthcare settings (Dummond et al., 2011), despite our finding no association between OLD and healthcare variables in this study. Less than half of this cohort (45.2 %) reported receiving healthcare in the past 6 months and a similar proportion (40.7 %) reported not going to see a doctor or healthcare provider even if they perceived the need to go. While 50 % of PWID in Baltimore had a diagnosis of OLD or emphysema from a physician (Dummond et al., 2011), only 9.6 % and 10.6 %, respectively, had these diagnoses among those with OLD in our cohort; however, 44.7 % reported shortness of breath (dyspnea) suggesting that OLD is underdiagnosed among PWID in San Diego, CA. Dyspnea is one of the most commonly reported symptoms of COPD and is part of its pathophysiology (Anzueto and Miravitlles, 2017). Despite experiencing symptoms indicative of OLD (i.e. dyspnea), few in this cohort sought primary care. PWID with OLD were less likely to seek care because they expected their visit to be unhelpful, they would receive bad news, or they would be mistreated. Prior studies report less access to healthcare among PWID compared to the general population (Chitwood et al., 1999), which could result in underutilization of primary healthcare services. Aside from the obstacles perceived by PWID, healthcare providers also cite that insufficient education on the “unique and demanding nature of PWIDs” (Lang et al., 2013) as an additional obstacle to care.

In addition, PWID may over-utilize emergency department care for injection-related complications (Kerr et al., 2004; Raven et al., 2009). A slight trend of over-utilization was seen in those with OLD; participants only reported on emergency department visits in the past 6 months, which might have attenuated this finding. Specialized treatment programs however were heavily utilized with nearly 80 % having received substance use treatment in their lifetime. Screening for OLD remains important in this underserved population, and better access to healthcare is crucial.

The SARS-CoV-2 virus responsible for a pandemic of novel coronavirus disease (COVID-19) that began in 2019 disproportionately affects older individuals, particularly those with underlying immunosuppressive conditions and lung disease such as COPD (Chinese
Mortality rates for COVID-19 are reportedly higher for those with chronic respiratory diseases (6.3 % vs 2.3 % overall). Our findings suggest that PWID should be considered an additional high-risk group for developing complications from COVID-19 due to the high prevalence and under-diagnoses of OLD. PWID are also thought to be at higher risk of infection, transmission, and complications from the virus due to the high prevalence of homelessness and incarceration, which make it difficult to maintain social distancing and adequate hygiene precautions. More research is needed to understand the associations between COVID-19 case outcomes and a history of substance abuse as well as the impact caused by the global pandemic (National Institute on Drug Abuse (NIDA), 2020). Clinicians need to be aware of the special challenges in caring for PWID and not postpone rehabilitation efforts (Ornell et al., 2020).

This study had limitations that should be taken into consideration when interpreting the findings. It did not measure the types and quantities of potential contaminants found in the drugs injected by participants. Therefore, duration of injection drug use and frequency of injection in the last 6 months were used as proxies for cumulative

### Table 2
Respiratory-related symptoms and diagnoses, and health care utilization by obstructive lung disease (OLD) status among persons who inject drugs, San Diego, CA.

|                          | Overall (n = 516) | OLD (n = 94) | No OLD (n = 422) | p-value* |
|--------------------------|------------------|--------------|------------------|----------|
| Shortness of breath in last month, n (%) |                  |              |                  |          |
| No                       | 352 (68.2)       | 52 (55.3)    | 300 (71.1)       | –        |
| Yes                      | 164 (31.8)       | 42 (44.7)    | 122 (28.9)       | 0.003    |
| Self-reported physician diagnosis of emphysema, n (%) |              |              |                  |          |
| No                       | 496 (96.1)       | 84 (89.4)    | 412 (97.6)       | –        |
| Yes                      | 20 (3.9)         | 10 (10.6)    | 10 (2.4)         | < 0.001  |
| Self-reported physician diagnosis of COPD, n (%) |              |              |                  |          |
| No                       | 477 (92.4)       | 85 (90.4)    | 392 (92.9)       | –        |
| Yes                      | 39 (7.6)         | 9 (9.6)      | 30 (7.1)         | 0.414    |
| Self-reported physician diagnosis of asthma, n (%) |              |              |                  |          |
| No                       | 422 (82.2)       | 76 (80.9)    | 348 (82.5)       | –        |
| Yes                      | 92 (17.8)        | 18 (19.2)    | 74 (17.5)        | 0.712    |
| Self-reported physician diagnosis of other lung disease, n (%) |              |              |                  |          |
| No                       | 481 (93.2)       | 83 (88.3)    | 398 (94.3)       | –        |
| Yes                      | 35 (6.8)         | 11 (11.7)    | 24 (5.7)         | 0.036    |
| Health coverage/insurance in past 6 months, n (%) |              |              |                  |          |
| No                       | 257 (49.8)       | 39 (41.5)    | 218 (51.7)       | –        |
| Yes                      | 257 (49.8)       | 55 (58.5)    | 202 (47.9)       | 0.068    |
| Don’t know**             | 2 (0.4)          | 0 (0.0)      | 2 (0.5)          |          |
| Received healthcare in the past 6 months, n (%) |              |              |                  |          |
| No                       | 283 (54.8)       | 48 (51.1)    | 235 (55.7)       | –        |
| Yes                      | 233 (45.2)       | 46 (48.9)    | 187 (44.3)       | 0.415    |
| Hospitalized in past 6 months, n (%) |              |              |                  |          |
| No                       | 424 (82.2)       | 79 (84.0)    | 345 (81.8)       | –        |
| Yes                      | 92 (17.8)        | 15 (16.0)    | 77 (18.3)        | 0.600    |
| Visited emergency department in past 6 months, n (%) |              |              |                  |          |
| No                       | 339 (65.7)       | 69 (73.4)    | 270 (64.0)       | –        |
| Yes                      | 177 (34.3)       | 25 (26.6)    | 152 (36.0)       | 0.082    |
| Visited out-patient clinic in past 6 months, n (%) |              |              |                  |          |
| No                       | 370 (71.7)       | 69 (73.4)    | 301 (71.3)       | –        |
| Yes                      | 146 (28.3)       | 25 (26.6)    | 121 (28.7)       | 0.686    |
| Perceived need to see a doctor or healthcare provider for physical or emotional problems, but did not go in past 6 months, n (%) |              |              |                  |          |
| No                       | 305 (59.1)       | 65 (69.2)    | 240 (56.9)       | –        |
| Yes                      | 210 (40.9)       | 29 (30.9)    | 181 (42.9)       | 0.030    |
| Don’t know**             | 1 (0.2)          | 0 (0.0)      | 1 (0.2)          |          |
| Main reason for not seeking medical care when needed in past 6 months, n (%) |              |              |                  |          |
| Visit not expected to be helpful, avoidance of bad news | 18 (3.5)       | 5 (5.3)     | 13 (3.1)         | 0.021    |
| Fear of hostility, disrespect, or arrest | 12 (2.3)       | 3 (3.2)     | 9 (2.1)          | 0.065    |
| Too embarrassed, ashamed, tired, sleepy, lazy, depressed, ill, weak, sick, or busy to go | 45 (8.7)       | 6 (6.4)     | 39 (9.2)         | 0.247    |
| Transportation issues | 12 (2.3)       | 1 (1.1)     | 11 (2.6)         | 0.824    |
| No insurance, too expensive | 61 (11.8)   | 4 (4.3)     | 57 (13.5)        | –        |
| Other                    | 52 (10.1)        | 7 (7.5)      | 45 (10.7)        | 0.226    |
| Not applicable           | 315 (61.1)       | 68 (72.3)    | 247 (58.5)       | –        |
| Don’t know**             | 1 (0.2)          | 0 (0.0)      | 1 (0.2)          |          |
| Ever in substance use treatmentb, n (%) |              |              |                  |          |
| No                       | 106 (20.5)       | 14 (14.9)    | 92 (21.8)        | –        |
| Yes                      | 410 (79.5)       | 80 (85.1)    | 330 (78.2)       | 0.134    |
| Type of substance use treatment in lifetime, n (%) |              |              |                  |          |
| Drugs only               | 269 (52.1)       | 54 (57.5)    | 215 (51.0)       | –        |
| Alcohol only             | 18 (3.5)         | 5 (5.3)      | 13 (3.1)         | 0.437    |
| Both, drugs and alcohol | 123 (23.8)       | 21 (22.3)    | 102 (24.2)       | 0.484    |
| Not applicable           | 106 (20.5)       | 14 (14.9)    | 92 (21.8)        |          |
| Number of times in substance use treatment, n = 391 Median (IQR) | 3 (2 − 5) | 4 (2 − 6) | 3 (1 − 5) | 0.689 |

Abbreviations: IQR: interquartile range. SD: standard deviation.  
*P-values were based on Chi-square test, t-test, or simple logistic regression.  
**Participants that “don’t know” or “refuse to answer” were excluded from the analysis. Values are shown for reporting purposes.  
*Variables are descriptive only and were not considered for multivariable analysis.  
* Treatment includes rehabilitation center, methadone or other medications, or other programs.  

Center for Disease Control and Prevention, 2020. Mortality rates for COVID-19 are reportedly higher for those with chronic respiratory diseases (6.3 % vs 2.3 % overall). Our findings suggest that PWID should be considered an additional high-risk group for developing complications from COVID-19 due to the high prevalence and under-diagnoses of OLD. PWID are also thought to be at higher risk of infection, transmission, and complications from the virus due to the high prevalence of homelessness and incarceration, which make it difficult to maintain social distancing and adequate hygiene precautions. More research is needed to understand the associations between COVID-19 case outcomes and a history of substance abuse as well as the impact caused by the global pandemic (National Institute on Drug Abuse (NIDA), 2020). Clinicians need to be aware of the special challenges in caring for PWID and not postpone rehabilitation efforts (Ornell et al., 2020).  

This study had limitations that should be taken into consideration when interpreting the findings. It did not measure the types and quantities of potential contaminants found in the drugs injected by participants. Therefore, duration of injection drug use and frequency of injection in the last 6 months were used as proxies for cumulative
exposure to these contaminants. Further research is needed to verify whether injecting contaminants caused OLD. Factors such as second-hand smoke, air pollution, occupational dust or fumes, and other lung irritants were not measured, and might contribute to the overall burden whether injecting contaminants caused OLD. Further research is needed to verify with obstructive lung disease (OLD) among persons who inject drugs, San H.J. Koslik, et al.

Table 3

Multivariable logistic regression analysis of factors independently associated with obstructive lung disease (OLD) among persons who inject drugs, San Diego, CA (n = 513).

| Race               | Adjusted Odds Ratio* (95% Confidence Interval) | p-value |
|--------------------|-----------------------------------------------|---------|
| Non-Black          | 1.00                                          |         |
| Black              | 2.66 (1.37, 5.17)                              | 0.004   |
| Pack-years smoked (per 5 pack-years) | 1.06 (1.01, 1.12)                              | 0.026   |
| Years injecting drugs (per 5 years) | 1.13 (1.01, 1.27)                              | 0.030   |

* Adjusted for age, a known risk factor for COPD (Global Initiative for Chronic Obstructive Lung Disease, 2018), and all other variables in the model.

5. Conclusions

OLD prevalence was high in this cohort of PWID and consistent with findings from PWID elsewhere (Drummond et al., 2011). We also found a high prevalence of previously undiagnosed and untreated OLD in symptomatic PWID.

While prior research found a relationship between injection drug use and OLD, this study was the first to address whether injection-related factors were associated with OLD in a cohort made up entirely of PWID. This study is also the first to identify an association between duration of injection drug use and OLD, although the mechanisms for this association need further exploration. It is unclear whether an accumulation of exposure to excipients in the drugs or another factor contributed to this relationship. Future research is needed that more precisely measures exposure to injected particles. Smoking also continues to be an important contributor to OLD in PWID. Thus, smoking cessation programs in this population remain extremely pertinent.

Role of funding source

The Study of Tuberculosis, AIDS and Hepatitis C Risk (STAHRII) was funded by the National Institutes of Drug Abuse (NIDA) grant #R01 DA031074 (PI: Richard S. Garfein). The funding source had no involvement in the study design, the collection, analysis and interpretation of data or in the writing of the report and in the decision to submit the article for publication.

CRediT authorship contribution statement

Hayley J. Koslik: Conceptualization, Methodology, Formal analysis, Writing - original draft. Jisha Joshua: Writing - review & editing. Jazmine Cuevas-Mota: Investigation, Data curation, Writing - review & editing. Daniel Goba: Conceptualization, Writing - review & editing. Eyal Oren: Methodology, Writing - review & editing. John E. Alcaraz: Methodology, Writing - review & editing. Richard S. Garfein: Conceptualization, Methodology, Writing - original draft, Supervision, Funding acquisition.

Declaration of Competing Interest

Dr. Garfein received a grant from the National Institutes of Health to conduct this study.

Acknowledgements

The authors are grateful to the study participants for sharing their stories and making this research possible.

References

Alcapes, P., Friedland, G., 1995. Injection drug use and human immunodeficiency virus infection. Clin. Infect. Dis. 20, 1467–1479.
Anzueto, A., Miravitlles, M., 2017. Pathophysiology of dyspnea in COPD. Postgrad. Med. 129, 366–374.
Armenta, R.F., Collins, K.M., Stratheude, S.A., Bulterys, M.A., Munoz, F., Cuevas-Mota, J., Chiles, P., Garfein, R.S., 2017. Mycobacterium tuberculosis infection among persons who inject drugs in San Diego, California. Int. J. Tuberc. Lung Dis. 21, 425–431.
Bhatt, S.P., Kim, Y.I., Harrington, K.F., Hokanson, J.E., Lut, S.M., Cho, M.H., DeMeo, D.L., Wells, J.M., Make, B.J., Rennard, S.I., Washko, G.R., Foreman, M.G., Tabshin, D.P., Wise, R.A., Dransfield, M.T., Bailey, W.C., 2018. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax 73, 414–421.
Byrne, A.L., Marais, B.J., Xie, M.D., Lecca, L., Marks, G.B., 2015. Tuberculosis and chronic respiratory disease: a systematic review. Int. J. Infect. Dis. 32, 138–146.
Chatilla, W.M., Hoffman, E.A., Gaughan, J., Robinovitch, S.G., Criner, G.J., 2006. Advanced emphysema in African-American and white patients: do differences exist? Chest 130, 108–118.
Chinese Center for Disease Control and Prevention, 2020. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 41, 145–151.
Chitwood, D.D., McBride, D.C., French, M.T., Comberford, M., 1999. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst. Use Misuse 34, 727–746.
Clarke, J.G., Stein, M.D., McCarty, K.A., Gogineni, A., 2001. Interest in smoking cessation among injection drug users. Am. J. Addict. 10, 159–166.
Crotbers, K., Butt, A.A., Gibert, C.L., Rodriguez-Barradas, M.C., Crystal, R., Justice, A.C., Veterans Aging Cohort 5 Project Team, 2006. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 130, 1326–1333.
de Marco, R., Accordini, S., Marcon, A., Cerveri, I., Anto, J.M., Gislason, T., Heinrich, J., Janssen, C., Jarvis, D., Kuenzli, N., Leynaert, B., Sunyer, J., Sanches, C., Wijst, M., Burney, P., 2011. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am. J. Respir. Crit. Care Med. 183, 891–897.
Dransfield, M.T., Davis, J.J., Herald, L.B., Bailey, W.C., 2006. Racial and gender differences in susceptibility to tobacco smoke among patients with chronic obstructive pulmonary disease. Respir. Med. 100, 1110–1116.
Drummond, M.B., Kirk, G.D., Astemborski, J., McCormack, M.C., Marshall, M.M., Mehta, S.H., Washko, R.A., Merlo, C.A., 2011. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. Int. J. Chron. Obstruct. Pulmon. Dis. 6, 89–95.
Drummond, M.B., Kirk, G.D., Astemborski, J., Marshall, M.M., Mehta, S.H., McDyer, J.F., Brown, R.H., Washko, R.A., Merlo, C.A., 2012. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax 67, 309–314.
Feldman, T.A., McCall, S.J., Reams, B.D., Roggli, V.L., Palmer, S.M., Howell, D.N., 2005. Pulmonary embolization of microcrystalline cellulose in a lung transplant recipient. J. Heart Lung Transplant. 24, 624.
Foreman, M.G., Zhang, L., Murphy, J., Hannel, N.N., Make, B., Hokanson, J.E., Washko, G., Regan, E.A., Crapo, J.D., Silverman, E.K., DeMeo, D.L., COPDGene Investigators, 2011. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and african american race in the COPDGene study. Am. J. Respir. Crit. Care Med. 184, 414–420.
Ganeshen, S., Fei, J., Saldana, M., Kalasinska, V.F., Lewin-Smith, M.R., Tomasheski Jr., J.F., 2003. Embolized crovipodeovin (polyvinyl-2-pyrolidone) in the lungs of intravenous drug users. Mod. Pathol. 16, 286–292.
Global Initiative for Chronic Obstructive Lung Disease, 2018. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 Report). Retrieved from https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov.WMS.pdf (Accessed on 18 May 2019).
Gorde, R., Suarez-Valor, M., Martin-Robles, I., Sanjuan-Lopez, F., Cano-Jimenez, E., Castro-Anon, O., Perez de Llano, L.A., 2018. Mortality in COPD patients according to clinical phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 1435–1439.
Gotway, M.B., Marder, S.R., Hanks, D.K., Leung, J.W., Dawn, S.K., Gean, A.D., Reddy, G.P., Arasa, P.A., Webb, W.R., 2002. Thoracic complications of illicit drug use: an organ system approach. Radiographics 22 (Spec No), S119–S135.
Griffith, C.G., Raval, J.S., Nichols, L., 2012. Intravascular talcosis due to intravenous drug use is an underrecognized cause of pulmonary hypertension. Pulm. Med. 2012, 6.
Guaraccino, A.J., Ray, S.M., Finch, C.K., Self, T.H., 2013. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoeconomics. Outcomes Res. 5, 235–245.
Guider, G., Brenner, S., Angermann, C.E., Ertl, G., Held, M., Sachs, A.P., Lammers, J.W., Zanen, F., Hoex, A.W., Stork, S., Rutten, F.H., 2012. “GOLD or lower limit of normal
